Physician profile
Peter K Keller
NPI 1639189038
$3,409.30
in general payments reported to CMS, 2019-2025
23 companies · $30.34 in 2025
The $30.34 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,788 · 2020: $526 · 2022: $41.44 · 2024: $23.67 · 2025: $30.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $384.72 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $374.60 | 2019-2020 | |
| Medtronic Vascular, INC. | $305.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $292.07 | 2019-2020 | |
| Boston Scientific Corporation | $281.03 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $270.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.69 | 2019-2020 | |
| Abbott Laboratories | $185.79 | 2019 | |
| Pfizer INC. | $185.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $152.96 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $120.08 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.81 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $108.22 | 2019-2020 | |
| Amarin Pharma, INC. | $91.34 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.14 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $51.69 | 2019-2020 | |
| Gilead Sciences, INC. | $46.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.23 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $21.94 | 2020 | |
| Philips North America LLC | $20.49 | 2022 | |
| Glaxosmithkline, LLC. | $19.42 | 2019 | |
| Braemar Manufacturing, LLC | $16.39 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.